GlassScriptPhysician profile
Bonnie William Thomas
NPI 1851321467
$37,527.03
in general payments reported to CMS, 2019-2025
22 companies · $3,117 in 2025
The $3,117 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $2,788 · 2021: $14K · 2022: $4,870 · 2023: $4,264 · 2024: $7,103 · 2025: $3,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,465 · Honoraria: $6,000 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,464.91 |
| Honoraria | $6,000.00 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $25,211.93 | 2020-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Gilead Sciences, INC. | $4,885.97 | 2019-2025 | Sunlenca, Biktarvy |
| Viiv Healthcare Company | $4,190.39 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $760.57 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $680.25 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $623.17 | 2019-2025 | Mavyret |
| Janssen Products, LP | $207.58 | 2019 | |
| Emd Serono, INC. | $197.39 | 2023-2025 | Serostim |
| Uswm, LLC | $194.22 | 2022-2023 | Zimhi, Lucemyra |
| Myovant Sciences INC. | $111.63 | 2021 | |
| Janssen Scientific Affairs, LLC | $96.03 | 2019-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $55.43 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $51.48 | 2021-2025 | Sublocade |
| Novo Nordisk INC | $48.07 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $47.43 | 2023-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.43 | 2025 | Cobenfy |
| Exact Sciences Corporation | $25.13 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $24.18 | 2024 | Mounjaro, Zepbound |
| Phadia US INC. | $21.56 | 2021 | |
| Hologic Sales and Service, LLC | $14.85 | 2019 | |
| Glaxosmithkline, LLC. | $14.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonnie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.